TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BetterLife Pharma ( (TSE:BETR) ) has issued an announcement.
BetterLife Pharma has appointed Daniel Carcillo, a former NHL player and advocate for traumatic brain injury (TBI) survivors, as a Corporate Advisor to advance the development of BETR-001, focusing on TBI, cluster headaches, and migraines. Carcillo’s personal experience with brain trauma and his advocacy work are expected to provide valuable insights, potentially enhancing the company’s position in the biotech industry and offering hope to stakeholders seeking innovative treatments for neurological disorders.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.
BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic derivative of LSD, aimed at treating various neurological disorders. The company is also exploring strategic alternatives for a drug candidate targeting viral infections.
Average Trading Volume: 127,125
Technical Sentiment Signal: Sell
Current Market Cap: C$8.35M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.